KR20080090101A - Health functional foods using seaweed foods and their manufacturing method - Google Patents
Health functional foods using seaweed foods and their manufacturing method Download PDFInfo
- Publication number
- KR20080090101A KR20080090101A KR1020070033187A KR20070033187A KR20080090101A KR 20080090101 A KR20080090101 A KR 20080090101A KR 1020070033187 A KR1020070033187 A KR 1020070033187A KR 20070033187 A KR20070033187 A KR 20070033187A KR 20080090101 A KR20080090101 A KR 20080090101A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- calcium
- cholesterol
- spiruna
- lyophilized powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241001474374 Blennius Species 0.000 title description 15
- 230000036541 health Effects 0.000 title description 10
- 235000013305 food Nutrition 0.000 title description 7
- 235000013376 functional food Nutrition 0.000 title description 7
- 238000004519 manufacturing process Methods 0.000 title description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 68
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 29
- 239000011575 calcium Substances 0.000 abstract description 29
- 229910052791 calcium Inorganic materials 0.000 abstract description 29
- 235000012000 cholesterol Nutrition 0.000 abstract description 26
- 239000002775 capsule Substances 0.000 abstract description 15
- 206010019133 Hangover Diseases 0.000 abstract description 12
- 241001200842 Capsosiphon fulvescens Species 0.000 abstract description 7
- 235000015872 dietary supplement Nutrition 0.000 abstract description 6
- 235000013361 beverage Nutrition 0.000 abstract description 5
- 230000007774 longterm Effects 0.000 abstract description 4
- 235000013402 health food Nutrition 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 239000008176 lyophilized powder Substances 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 235000019441 ethanol Nutrition 0.000 description 18
- 238000009472 formulation Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 229920002261 Corn starch Polymers 0.000 description 7
- 241000195493 Cryptophyta Species 0.000 description 7
- 239000008120 corn starch Substances 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 description 5
- 229930002875 chlorophyll Natural products 0.000 description 5
- 235000019804 chlorophyll Nutrition 0.000 description 5
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 240000002900 Arthrospira platensis Species 0.000 description 3
- 235000016425 Arthrospira platensis Nutrition 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 3
- 239000002374 bone meal Substances 0.000 description 3
- 229940036811 bone meal Drugs 0.000 description 3
- 150000001746 carotenes Chemical class 0.000 description 3
- 235000005473 carotenes Nutrition 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 235000020510 functional beverage Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 229940082787 spirulina Drugs 0.000 description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 3
- 229940013618 stevioside Drugs 0.000 description 3
- 235000019202 steviosides Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 239000007958 cherry flavor Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000176 sodium gluconate Substances 0.000 description 2
- 235000012207 sodium gluconate Nutrition 0.000 description 2
- 229940005574 sodium gluconate Drugs 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 206010061291 Mineral deficiency Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 241000083869 Polyommatus dorylas Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- YXZRCLVVNRLPTP-UHFFFAOYSA-J turquoise blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Cu+2].NC1=NC(Cl)=NC(NC=2C=C(NS(=O)(=O)C3=CC=4C(=C5NC=4NC=4[N-]C(=C6C=CC(=CC6=4)S([O-])(=O)=O)NC=4NC(=C6C=C(C=CC6=4)S([O-])(=O)=O)NC=4[N-]C(=C6C=CC(=CC6=4)S([O-])(=O)=O)N5)C=C3)C(=CC=2)S([O-])(=O)=O)=N1 YXZRCLVVNRLPTP-UHFFFAOYSA-J 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/60—Edible seaweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/10—Natural spices, flavouring agents or condiments; Extracts thereof
- A23L27/12—Natural spices, flavouring agents or condiments; Extracts thereof from fruit, e.g. essential oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 매생이(capsosiphon fulvescens(Mesangi))를 함유한 기능성 건강식품에 관한 것으로, 보다 상세히는 매생이, 스피루나, 칼슘을 주요성분으로 함유한 장기간 안정성이 확보된 정제, 캡슐제, 음료형태의 숙취해소 및 콜레스테롤 저하용 건강기능식품에 관한 것이다.The present invention relates to a functional health food containing capsosiphon fulvescens (Mesangi), and more particularly, hangover in the form of tablets, capsules, beverages that ensure long-term stability, containing spiruna, calcium as a main component The present invention relates to a dietary supplement for eliminating and lowering cholesterol.
Description
본 발명은 해조류 매생이(Capsosiphon fulvescens(Mesangi))를 이용하여 숙취해소용 및 콜레스테롤 저하작용을 갖는 건강기능성 식품 및 그의 제조방법에 관한 것으로, 건강기능성 식품으로서 정제화 및 캡슐화함에 있으며, 또한 일차 가공처리된 매생이를 추출하여 음료를 만드는 데 있다.The present invention relates to a health functional food having a hangover resolution and cholesterol lowering effect using a seaweed algae (Capsosiphon fulvescens (Mesangi)), and a method for preparing the same as a health functional food. It is in making a drink by extracting the falcons.
해조류 매생이는 대한민국 서해 및 남해지역 바다에서 1년 중 10월 중순부터 이듬해 2월 말까지 수확하여 수세하고 포장하여 일반 조리식품으로 판매유통되고 있다.Algae falcons are harvested, washed, packaged and sold as general cooked food from mid-October to the end of February of the year.
그러나 이러한 제품의 문제점은 보관에 따른 제품의 신선도 및 여러 가지 유통에 문제점을 많이 가지고 있으며 기후, 온도에 따른 보관 조건에 따라 쉽게 변질되기 쉬우며 또한 수분이 함유되어 있는 상태에서 냉동 운반 등의 문제와 장시간 보관할 수 없는 문제점 등이 있다.However, the problems of these products have a lot of problems in the freshness and various distribution of the product according to the storage, and easy to deteriorate according to the storage conditions according to the climate and temperature, and also the problems such as freezing transport in the state containing water There is a problem that can not be stored for a long time.
이러한 문제점들을 개선하고 누구나가 사계절 중 언제든지 쉽고 간편하게 섭취할 수 있는 방법을 모색하여 오던 중 본 발명을 하게 되었다.To improve these problems and to find a way that anyone can easily and easily ingest at any time during the four seasons came to the present invention.
본 발명에서는 이러한 문제점(보관, 운반, 장기적인 섭취용이, 안전성)들을 모두 개선하여 누구나가 언제든지 편리하고 안전하게 섭취할 수 있도록 고안된 것이다.In the present invention, all of these problems (storage, transport, long-term intake, safety) are designed to be easily and safely ingested by anyone at any time.
즉, 본 발명은 바다의 보고라 일컫는 매생이에 함유되어 있는 아미노산 및 비타민, 단백질, 엽록소 등은 사람이 생명을 유지하는데 있어서 없으면 안 되는 필수적인 성분들이다. 그러나 이러한 필수성분들을 일상생활에서 음식물을 통하여 공급받고 있지만 음식물만으로는 충분한 공급을 받지 못하는 경우가 대부분이다.That is, in the present invention, amino acids, vitamins, proteins, chlorophyll, and the like contained in falcons, referred to as sea treasury, are essential ingredients for humans to maintain life. However, these essential ingredients are supplied through food in daily life, but most of them do not receive enough food alone.
본 발명은 일상생활에서 충분히 공급받지 못하여 몸의 건강상태를 잃어버리는 사람들에게 간편하고 안전하게 충분한 영양공급을 하고자 하는 것이 본 발명의 과제이다.It is an object of the present invention to provide a simple and safe enough nutrition to those who do not receive enough in daily life and lose their health.
본 발명은 매생이(Capsosiphon fulvescens), 스피루나(Spiruna) 및 칼슘을 주재료로 함유한 숙취해소 및 콜레스테롤 저하용 건강기능성 식품에 관한 것이다.The present invention relates to a dietary supplement for hangover and cholesterol lowering containing capsosiphon fulvescens, spiruna and calcium as main ingredients.
보다 상세하게는,More specifically,
매생이(Capsosiphon fulvescens, Mesangi) 동결건조분말 70-85 중량%, 스피루나 5-10 중량%, 해조칼슘, 탄산칼슘, 식용우골분 또는 소성칼슘 중에서 선택된 칼슘성분 5-10 중량%, 유당 또는 옥수수 전분 중에서 선택된 부형제 3-8 중량%, 스테아린산 마그네슘, 글루콘산 전분 나트륨 또는 탈크 중에서 선택된 활택제 1-3 중량%, 또는 추가로 히드록시프로필 셀룰로오스 또는 포비돈 중에서 선택된 코팅기제 1-3 중량%로 구성된 정제 또는 캅셀제형의 건강기능식품에 관한 것이며,Capsosiphon fulvescens (Mesangi) 70-85% by weight of lyophilized powder, 5-10% by weight of spiruna, 5-10% by weight of calcium components selected from seaweed calcium, calcium carbonate, edible bone flour or calcined calcium, lactose or corn starch Tablets consisting of 3-8% by weight of an excipient selected from 1 to 3% by weight of a lubricant selected from magnesium stearate, sodium gluconate or talc, or 1-3% by weight of a coating base selected from hydroxypropyl cellulose or povidone, or It relates to the health functional food of capsule type,
매생이(Capsosiphon fulvescens, Mesangi) 동결건조분말 70-85 중량%, 스피루나 5-10 중량%, 해조칼슘, 탄산칼슘, 식용우골분 또는 소성칼슘 중에서 선택된 칼슘 성분 5-10 중량%, 유당 또는 옥수수 전분 중에서 선택된 부형제 3-8 중량%를 혼합하여 균질화 시킨 후, 스테아린산 마그네슘, 글루콘산 전분 나트륨 또는 탈크 중에서 선택된 활택제 1-3 중량%를 넣고 혼합시킨 후 타정 또는 캡슐에 충진하거나, 히드록시프로필 셀룰로오스 또는 포비돈 중에서 선택된 코팅기제 1-3 중량%로 코팅시킴을 특징으로 하는 정제 또는 캡슐제형의 건강기능성 식품의 제조방법에 관한 것이다.Capsosiphon fulvescens (Mesangi) 70-85% by weight lyophilized powder, 5-10% by weight spiruna, 5-10% by weight calcium component selected from algae calcium, calcium carbonate, edible bone flour or calcined calcium, lactose or corn starch 3 to 8% by weight of the excipient selected from the mixture is homogenized, and then mixed with 1-3% by weight of the lubricant selected from magnesium stearate, starch sodium gluconate or talc and mixed into tablets or capsules, or hydroxypropyl cellulose or The present invention relates to a method for producing a dietary supplement of the form of a tablet or capsule, characterized by coating with 1-3 wt% of the coating base selected from povidone.
또한, 추가적으로 본 발명은 건강기능성 음료를 제공하는 것이며, 매생이(Capsosiphon fulvescens, Mesangi) 동결건조분말을 5배 중량의 에탄올로 5-40 ℃에서 3분간 3-4회 초음파 추출(세기; 75-520 W, 진동수; 20,000±2,000 회/초)하여 여과한 후, 65-85 ℃, 600-760 mmHg 조건하에서 부피를 1/5로 감압, 농축시켜 얻은 매생이 추출물 20-40 중량%; 스피루나 1-3 중량%; 해조칼슘, 탄산칼슘, 식용우골분 또는 소성칼슘 중에서 선택된 칼슘 성분 0.3-1 중량%; 설탕, 꿀, 아스파탐, 스테비오사이드, 만니톨, 올리고당, 과당, 포도당 중에서 선택된 1종 이상의 감미제 30-60 중량%; 구연산, 비타민C, 구연산 나트륨, 소금(NaCl) 중에서 선택된 1종의 산미제 3-6 중량%; 허브향, 오렌지향 또는 체리향 중에서 선택된 1종의 향료 0.5-1 중량%; 및 정제수로 구성된 건강기능성 음료에 관한 것이며, 나아가 매생이 추출물 20-40 중량%, 스피루나 1-3 중량%; 해조칼슘, 탄산칼슘, 식용우골분 또는 소성칼슘 중에서 선택된 칼슘 성분 0.3-1 중량%; 설탕, 꿀, 아스파탐, 스테비오사이드, 만니톨, 올리고당, 과당, 포도당 중에서 선택된 1종 이상의 감미제 30-60 중량%; 구연산, 비타민C, 구연산 나트륨, 소금(NaCl) 중에서 선택된 1종의 산미제 3-6 중량%; 허브향, 오렌지향 또는 체리향 중에서 선택된 1종의 향료 0.5-1 중량%에 정제수를 가하여 균질화 시키고, 전체 100 중량%로 한 다음 여과하여 제조함을 특징으로 하는 건강기능 음료의 제조방법에 관한 것이다.In addition, the present invention is to provide a health functional beverage, capsosiphon fulvescens (Mesangi) lyophilized powder with 5 times the weight of ethanol extracted 3-4 times at 5-40 ℃ for 3 minutes (intensity; 75-520 W, frequency: 20,000 ± 2,000 times / second), and filtered, and then, 20-40% by weight of the extract of perilla extract obtained by concentrating and reducing the volume to 1/5 under the conditions of 65-85 ° C. and 600-760 mmHg; Spiruna 1-3% by weight; 0.3-1% by weight of a calcium component selected from seaweed calcium, calcium carbonate, edible bone meal or calcined calcium; 30-60% by weight of one or more sweeteners selected from sugar, honey, aspartame, stevioside, mannitol, oligosaccharides, fructose, glucose; 3-6% by weight of one acidulant selected from citric acid, vitamin C, sodium citrate, salt (NaCl); 0.5-1% by weight of one flavor selected from herbal, orange or cherry flavors; And it relates to a functional beverage consisting of purified water, furthermore 20-40% by weight of extract persimmon, 1-3% by weight of spiruna; 0.3-1% by weight of a calcium component selected from seaweed calcium, calcium carbonate, edible bone meal or calcined calcium; 30-60% by weight of one or more sweeteners selected from sugar, honey, aspartame, stevioside, mannitol, oligosaccharides, fructose, glucose; 3-6% by weight of one acidulant selected from citric acid, vitamin C, sodium citrate, salt (NaCl); It relates to a method for producing a health functional beverage, characterized in that the homogenized by adding purified water to 0.5-1% by weight of one flavor selected from herbs, oranges or cherry flavors, and then filtered by 100% by weight. .
본 발명에서 매생이 동결건조분말은 남해안 각지에서 나는 해조류인 매생이(Capsosiphon fulvescens, Mesangi)를 10월 중순에서 2월 말까지 수확하여 수세, 동결건조하고, 미세분말화하여 섬유질을 제거한 100-200 메쉬체를 통과한 분말이다. 본 발명의 기능성 식품을 위해서는 캅셀 또는 정제의 전체중량의 70-85 중량% 또는 액체음료의 전체중량의 20-40 중량%가 제제의 안정성은 물론 매생이가 지닌 고 콜레스테롤의 저하 및 심혈관계질환예방, 숙취해소작용, 다이어트 및 비만예방효과 유지에 바람직하다. 식약청의 공식자료에 의하면, 매생이 효과로,In the present invention, the lyophilized lyophilized powder is harvested from mid-October to the end of February, which is a seaweed algae from all over the south coast, washed with water, lyophilized and finely powdered to remove 100-200 mesh bodies. The powder passed through. For the functional food of the present invention, 70-85% by weight of the total weight of the capsules or tablets or 20-40% by weight of the total weight of the liquid beverage is not only stable, but also lowers high cholesterol and prevents cardiovascular diseases. It is desirable for hangover relief, diet and obesity prevention. According to the official data of the FDA, every life is effective,
1) 유기산에 매우 약한 매생이는 부드럽고 소화가 잘된다.1) Very weak to organic acids, falcons are soft and digestible.
2) 철분, 칼륨, 요오드 등 각종 무기염류와 비타민 A, C 등을 다량 함유하고 있어, 어린이 성장발육촉진 및 골다공증 예방에 효과가 있다.2) It contains various inorganic salts such as iron, potassium, and iodine, and vitamins A and C, which are effective for promoting children's growth and preventing osteoporosis.
3) 위궤양이나 십이지장궤양을 예방하고 진정시키는 효과가 뛰어나 술 마신 후 숙취해소작용도 뛰어나다.3) It is excellent in preventing and calming gastric ulcer or duodenal ulcer.
4) 콜레스테롤 함량저하, 고혈압을 내리는 성분이 있으며, 변비가 있는 사람은 바로 효과가 있다고 소개되어 있다.4) lower cholesterol content, high blood pressure to reduce the components, people with constipation is said to be effective.
본 발명에서는 매생이의 숙취해소작용, 콜레스테롤 저하작용, 어린이 성장촉진작용 및 변비치료효능 등을 보강시키기 위하여 스피루나와 칼슘 성분을 추가로 함유하고 있다.In the present invention, spiruna and calcium components are further included to reinforce hangover, cholesterol lowering, children's growth promotion, and constipation treatment.
스피루나(Spiruna)는 스피루리나(Spirulina)라고도 하며, 스피루리나로 분류된 청록색의 남조류로 폭 10 마이크론, 길이 300-500 마이크론의 나선형을 하고 있으며, 끈질긴 생명력으로 이미 30억년전부터 지구상에 출현한 조류식물로서 인체에 필요한 영양분을 고루 함유하고 있어 건강보조식품으로 개발이 활발하게 이루어지고 있다. 그 구성성분으로는 식물성 단백질 70 %(소고기는 동물성 단백질 18 %), 카로틴 100-200 mg/100 g(카로틴은 체내에서 비타민 A로 변화된다), 식물성지방산 8 %, 비타민류인 A, B1, B2, B6, B12, E, 니코틴산, 엽산, 판토텐산이 다량 함유되어있고 핵산, 피코시아닌, 그리고 클로로필, 철, 칼슘 등이 함유되어 있다. 효과 면에서는 카로틴과 핵산은 활성산소를 무해화시켜 노화를 지연시켜주며, 고함량의 비 타민 B12와 철은 적혈구를 증가시켜주어, 유아, 병약자의 최고영양식으로 적합하다. 또 면역기능(자기치유력)을 높여주며, 혈중콜레스테롤을 감소시키고, 미네랄의 흡수율을 높여주며, 1.6 %나 되는 엽록소는 강력한 살균작용, 심장기능강화, 변비해소작용, 빈혈의 예방과 치유에 효과를 나타내며, 인류의 미래식품으로 지정, 우주항공사들의 우주식품으로 연구중에 있으며, 특히, 체질개선, 위궤양, 간장질환, 당뇨병, 췌장염, 백내장, 원형탈모증, 백혈구 감소증에 대한 치료효과가 있고 암예방, 다이어트 보조식품, 항 스트레스작용 등이 있다고 알려져 있다.Spiruna, also known as Spirulina, is a turquoise blue algae classified as spirulina, spiraling 10 microns wide and 300-500 microns long, and has been endowed with bird life that has appeared on Earth for 3 billion years ago. As it contains nutrients necessary for the human body, development is being actively made as a health supplement food. Its components include 70% vegetable protein (beef is 18% animal protein), carotene 100-200 mg / 100 g (carotene is converted to vitamin A in the body), 8% vegetable fatty acid, vitamins A, B 1 , It contains a lot of B 2 , B 6 , B 12 , E, nicotinic acid, folic acid and pantothenic acid, nucleic acid, phycocyanin, and chlorophyll, iron and calcium. In terms of effects, carotene and nucleic acid deplete free radicals and delay aging, and high levels of vitamin B 12 and iron increase red blood cells, making them ideal for infants and the sick. In addition, it boosts immune function (self healing), decreases blood cholesterol, improves absorption of minerals, and 1.6% of chlorophyll is effective in potent bactericidal action, strengthening heart function, relieving constipation, preventing and healing anemia. It is designated as the future food of human beings, and is being researched as a space food of astronauts.In particular, it has a therapeutic effect on constitution improvement, gastric ulcer, liver disease, diabetes, pancreatitis, cataracts, alopecia areata, leukopenia, and cancer prevention and diet. Supplements, anti-stress action is known.
본 발명에서 스피루나는 정제 또는 캅셀제의 전체중량의 5-10 중량% 또는 액체음료의 전체중량의 1-3 중량%를 함유하는 것이 제제화나 적절한 효능유지에 바람직하다.In the present invention, it is preferable for spiruna to contain 5-10% by weight of the total weight of tablets or capsules or 1-3% by weight of the total weight of liquid beverages for formulation or maintaining proper efficacy.
칼슘성분으로는 해조칼슘, 탄산칼슘, 식용우골분, 구연산 칼슘 또는 소성칼슘 중에서 선택된 1종을 추가적으로 함유하며, 성장발육촉진, 골다공증치료, 임산부 등 칼슘 보급제로 효능이 보강된 정제 또는 캡슐제로서 전체중량의 5-10 중량% 또는 액체음료의 전체중량의 0.3-1 중량%를 함유하는 것이 제제의 안정성이나 적절한 효능의 유지를 위하여 바람직하다.As a calcium component, it additionally contains one selected from seaweed calcium, calcium carbonate, edible bone meal, calcium citrate or calcined calcium, and it is a tablet or capsule supplemented with calcium supplements such as promoting growth and development, osteoporosis treatment and pregnant women. It is preferable to contain 5-10% by weight or 0.3-1% by weight of the total weight of the liquid beverage in order to maintain the stability of the preparation or the proper efficacy.
이하 본 발명의 내용을 실시예 및 시험예를 통하여 보다 구체적으로 설명하고자 한다. 이는 본 발명을 보다 더 상세하게 설명하기 위한 것으로 본 발명에 한정되어지는 것은 아니다.Hereinafter, the content of the present invention will be described in more detail with reference to Examples and Test Examples. This is intended to explain the present invention in more detail and is not limited to the present invention.
실시예 1. 매생이 동결건조분말의 제조. Example 1 . Preparation of lyophilized powders perennially.
대한민국 서해 및 남해지역 바다에서 1년 중 10월 중순부터 이듬해 2월 말까지 수확한 매생이(Capsosiphon fulvescens, Mesangi) 1,000 Kg을 수세한 후 동결건조(온도 : -10 ~ -170 ℃, 시간 : 24-48 hr)하여 분쇄기(함마밀)로 미세하게 분말화하여 100-200 메쉬체로 걸러 거친 섬유질을 제거한 매생이 동결건조분말 102 Kg을 얻었다.Freeze-dried (temperature: -10 ~ -170 ℃, time: 24-) after washing 1,000 Kg of Capsosiphon fulvescens (Mesangi) harvested from mid-October to the end of February of the year. 48 hr) was finely powdered by a pulverizer (hamma mill) and filtered through a 100-200 mesh sieve to obtain 102 Kg of lyophilized powder having been removed from coarse fibers.
실시예 2. 매생이 추출물의 제조. Example 2 . Preparation of Perennial Extracts.
실시예 1에서 얻은 매생이 동결건조분말 102 Kg을 중량대비 5배 무게의 70 % 에탄올을 가하여 5-40 ℃에서 30분씩 3-4회 정도 초음파추출(세기 : 75-520 W, 진동수 : 20,000 ± 2,000 회/초)하여 여과한 후, 65-85 ℃, 600-760 mmHg 조건하에서 부피를 최초부피의 1/5로 감압 농축시켜 최종농축액을 매생이 투여량의 무게비와 같게 한 매생이 추출물 100 L을 얻었다.Ultrasonic extraction was performed 3-4 times at 5-40 ° C. for 30 minutes at 70 kg of lyophilized powder 102 kg of lyophilized powder, which was obtained by weight 5 times by weight (intensity: 75-520 W, frequency: 20,000 ± 2,000 Per second), and the resultant was filtered and concentrated under reduced pressure to 1/5 of the original volume under the conditions of 65-85 ° C. and 600-760 mmHg to obtain 100 L of the extract of the perennial extract having the final concentration equal to the weight ratio of the perennial dose.
제제예 1. 정제. Formulation Example 1 . refine.
실시예 1에서 얻은 매생이 동결건조분말 70 중량%, 스피루나 10 중량%, 해조칼슘 10 중량%, 옥수수전분 8 중량%를 각각 100 mesh 체를 이용 사별하여 V형 혼합기에 넣고, 최종적으로 스테아린산 마그네슘 2 중량%를 넣어 20분간 혼합한 후, 정제기를 이용하여 정제의 강도(정제압력)가 3.5-5.5 Kg/㎠되게 타정하여 제조하였 다.70% by weight of lyophilized powder, 10% by weight of spiruna, 10% by weight of seaweed calcium, and 8% by weight of corn starch were added to a V-type mixer using 100 mesh sieve, and finally, magnesium stearate 2 After mixing for 20 minutes by weight, using a tablet machine was prepared by tableting so that the strength (purification pressure) of the tablet is 3.5-5.5 Kg / ㎠.
제제예 2. 정제. Formulation Example 2 . refine.
실시예 1에서 얻은 매생이 동결건조분말을 80 중량%, 스피루나 10 중량%, 해조칼슘 5 중량%, 옥수수전분 3 중량%를 각각 100 mesh 체를 이용 사별하여 V형 혼합기에 넣고, 최종적으로 스테아린산 마그네슘 1 중량%를 넣어 20분간 혼합한 후, 정제기를 이용하여 정제의 강도(정제압력)가 2.5-4.5 Kg/㎠되게 타정한 후, 분진을 제거한 다음, 필름코팅기(하이코타)에 넣고 에탄올에 히드록시프로필 셀룰로오스(HPC)을 녹여 정당 1 중량%되게 녹여 스프레이 코팅을 하여 제조하였다.Each of the lyophilized powders obtained in Example 1 were 80% by weight, 10% by weight of spiruna, 5% by weight of seaweed calcium, and 3% by weight of corn starch, respectively, using a 100 mesh sieve and placed in a V-type mixer, and finally magnesium stearate 1 weight% of the mixture was mixed for 20 minutes, and the tablet was tableted to have a strength (tablet pressure) of 2.5-4.5 Kg / cm 2, and then dust was removed, and then placed in a film coater (Hycota) and hydrated in ethanol. Roxypropyl cellulose (HPC) was melted to just 1% by weight to prepare a spray coating.
제제예 3. 정제. Formulation Example 3 . refine.
실시예 1에서 얻은 매생이 동결건조분말을 85 중량%, 스피루나 5 중량%, 해조칼슘 5 중량%, 옥수수전분 4 중량%를 각각 100 mesh 체를 이용 사별하여 V형 혼합기에 넣고 최종적으로 스테아린산 마그네슘 1 중량%를 넣어 20분간 혼합한 후 정제기를 이용하여 정제의 강도(정제압력)가 3.0-5.0 Kg/㎠되게 타정하여 제조하였다.Each of the lyophilized powders obtained in Example 1 were 85% by weight, 5% by weight of spiruna, 5% by weight of seaweed calcium, and 4% by weight of corn starch, respectively, using a 100 mesh sieve and placed in a V-type mixer. Finally, magnesium stearate 1 After mixing 20% by weight, the tablet was prepared by tableting so that the strength (tablet pressure) of the tablet was 3.0-5.0 Kg / cm 2.
제제예 4. 캡슐제. Formulation Example 4 . Capsules.
실시예 1에서 얻은 매생이 동결건조분말을 75 중량%, 스피루나 10 중량%, 해조칼슘 5 중량%, 옥수수전분 8 중량%를 각각 100 mesh 체를 이용 사별하여 V형 혼 합기에 넣고, 최종적으로 스테아린산 마그네슘 2 중량%를 넣어 20분간 혼합한 후, 캡슐 충전기를 이용하여 내용 충전량은 캡슐(2호, 1호, 0호) 크기에 따라 250-500 mg 되게 충전하여 제조하였다.The lyophilized powder obtained in Example 1 was 75% by weight of lyophilized powder, 10% by weight of spiruna, 5% by weight of seaweed calcium, 8% by weight of corn starch, respectively, using a 100 mesh sieve and put into a V-type mixer, and finally stearic acid After mixing for 2 minutes by adding 2% by weight of magnesium, the contents of the filling using a capsule filling machine was prepared by filling to 250-500 mg according to the size of the capsule (No. 2, No. 1, No. 0).
제제예 5. 캡슐제. Formulation Example 5 . Capsules.
실시예 1에서 얻은 매생이 동결건조분말 80 중량%, 스피루나 7.5 중량%, 해조칼슘 7.5 중량%, 옥수수전분 4 중량%를 각각 100 mesh 체를 이용 사별하여 V형 혼합기에 넣고 최종적으로 스테아린산 마그네슘 1 중량%를 넣어 20분간 혼합한 후 캡슐 충전기를 이용하여 내용 충전량은 캡슐(2호, 1호, 0호) 크기에 따라 250-500 mg되게 충전하여 제조하였다.Each weight of the lyophilized powder obtained in Example 1 was separated into 80% by weight of lyophilized powder, 7.5% by weight of spiruna, 7.5% by weight of seaweed calcium and 4% by weight of corn starch in a V-type mixer using 100 mesh sieve. After adding 20% of the mixture and mixing the contents using a capsule charger was prepared by filling the 250-500 mg according to the size of the capsule (No. 2, No. 1, No. 0).
제제예 6. 액제. Formulation Example 6 . Liquid.
실시예 2에서 얻은 매생이 동결건조분말의 에탄올 추출물 20 중량%, 스피루나 3 중량%, 해조칼슘 1 중량%, 설탕 10 중량%, 올리고당 20 중량%, 만니톨 3 중량%, 스테비오사이드 3 중량%, 구연산 3 중량%, 구연산 나트륨 2 중량%, 허브향 1.0 중량%를 균질화 시키고 물을 가하여 전체 100 중량%로 한 다음 1 마이크로필터를 이용하여 여과, 제조하였다.20% by weight of ethanol extract of lyophilized powder, 3% by weight of spiruna, 1% by weight of seaweed calcium, 10% by weight of sugar, 20% by weight of oligosaccharide, 3% by weight of mannitol, 3% by weight of stevioside, citric acid 3% by weight, sodium citrate 2% by weight, 1.0% by weight of the herb flavor was homogenized, water was added to 100% by weight, and then filtered and prepared using 1 micro filter.
제제예 7. 액제. Formulation Example 7 . Liquid.
실시예 2에서 얻은 매생이 동결건조분말의 에탄올 추출물 40 중량%, 스피루 나 1 중량%, 해조칼슘 0.3 중량%, 설탕 20 중량%, 올리고당 20 중량%, 구연산 3 중량%, 만니톨 2 중량%, 소금 2 중량%, 허브향 1.0 중량%에 물을 가하여 전체 100 중량%로 한 다음 1 마이크로필터를 이용하여 여과, 제조하였다.The ethanol extract of the lyophilized powder obtained in Example 2 was 40% by weight, 1% by weight of spiruna, 0.3% by weight of seaweed calcium, 20% by weight of sugar, 20% by weight of oligosaccharide, 3% by weight of citric acid, 2% by weight of mannitol, salt Water was added to 2% by weight and 1.0% by weight of the herb flavor to make 100% by weight, and then filtered and prepared using 1 micro filter.
실험예Experimental Example 1 One
제품에 사용되는 매생이 원재료 동결건조분말에 대하여 "건강기능성 식품 공전에 따른 엽록소 시험 및 조단백 시험"을 3회씩 실시하여 평균값을 구하였는바, 다음 표 1과 같았다.The average value of the lyophilized powder used for the product was determined by performing three times the "chlorophyll test and crude protein test according to the health functional foods" for the raw material lyophilized powder, as shown in Table 1 below.
표 1. (매생이 원재료 분말시험) Table 1 . (Raw raw material powder test)
실험예Experimental Example 2 2
상기에서 실시한 7가지 예에 대하여 관능검사 및 기타 제품이 가지는 성분검사 및 이화학적인 시험을 행하였는바, 다음 표 2와 3과 같았다.For the seven examples carried out above, the sensory test and the physical and chemical tests of the other products were carried out. The results are as shown in Tables 2 and 3 below.
표 2. (정제와 캅셀제) Table 2 . (Tablet and capsule)
표 3. (액제 음료) Table 3 . (Liquid drink)
실험예Experimental Example 3 3
숙취해소 작용에 관한 동물실험예. Experimental Example of Hangover Relief .
숙취란 술을 마신후 나타나는 두통, 설사, 식욕부진, 오심, 구토, 오한, 식은땀을 뜻하며 객관적인 증상으로는 인식, 운동능력저하, 혈핵학적 변화 및 호르몬 변화를 말한다.A hangover refers to headache, diarrhea, anorexia, nausea, vomiting, chills, and cold sweating after drinking alcohol. Objective symptoms include perception, decreased motor skills, hematologic changes, and hormonal changes.
그 원인으로는 탈수, 알코올 및 알코올 대사물(아세트알데히드, 포름알데히 드, 아세톤 등)의 독성, 흡수장애에 의한 영양소 결핍(혈당, 비타민, 무기질결핍)으로 알려져 있으며 그 정도는 개인에 따른 편차 즉, 유전적 소양 또는 환경상태(영양상태, 운동상태, 탈수정도, 건강상태)에 따라 정도의 차이가 매우 심함으로 따라서 숙취증상 도는 숙취해소의 과학적이고 객관적인 평가가 어려운 상태이나 본 발명에서는 알코올을 대조군으로 하여 시험군 매생이 분말 100 %와 매생이 분말 80 %, 스피루나 7.5 %, 해조칼슘 7.5 %를 혼합시키거나(제제예 5, 캡슐제 처방) 매생이 추출물 40 %, 스피루나 1 %, 해조칼슘 0.3 %를 혼합시켜(제제예 7, 액제 처방) 동물에게 인위적으로 경구 투여한 후 혈액 중 알코올 농도를 측정함으로써 숙취해소의 효과를 간접적으로 확인하였다.The causes include dehydration, toxicity of alcohols and alcohol metabolites (acetaldehyde, formaldehyde, acetone, etc.), nutrient deficiencies due to malabsorption (blood glucose, vitamins, mineral deficiencies), and the degree of variation according to individuals. That is, the degree of difference is very severe depending on genetic literacy or environmental conditions (nutrition state, exercise state, dehydration degree, health state), so the hangover symptoms are difficult to scientifically and objectively evaluate hangover resolution, but in the present invention alcohol As a control, 100% of the test group syphilis powder and 80% of the syphilis powder were mixed, 7.5% spiruna, 7.5% seaweed calcium (Formulation 5, capsule formulation), or 40% of medicinal extract, 1% spirulina, 0.3% algae calcium The effect of hangover relief was indirectly confirmed by mixing% (preparative example 7, liquid formulation) by artificially oral administration to animals and measuring the alcohol concentration in the blood.
1) 시험방법: 1) Test Method:
스프레이큐 도레이 랫트(Sprague Dawley rat)의 200-500 g 되는 숫컷을 고형사료와 음용수를 자유 섭취케 하여 1 주간 예비 사육한 후 알코올은 3 g/Kg의 양으로 경구 투여한다.200-500 g males of Sprague Dawley rats are freely fed with solid feed and drinking water for 1 week, followed by oral administration of 3 g / Kg of alcohol.
30 분 후에 알코올을 경구투여하고, 투여 후 1 시간, 3 시간, 5 시간 혈액을 채취한다.After 30 minutes, alcohol is orally administered and blood is collected for 1 hour, 3 hours, and 5 hours after administration.
혈액은 3,000 rpm에서 20 분간 원심분리 하여 혈청을 분리한 후, 에탄올(ethanol) 농도를 측정하였다.Blood was centrifuged at 3,000 rpm for 20 minutes to separate serum, and then ethanol concentration was measured.
표 4. (제제설계) Table 4 . (Product Design)
표 5. (실험동물설계) Table 5 . Experimental animal design
표 6. (결과 및 효과 평가) Table 6 . (Evaluation of results and effectiveness)
혈액 중 알코올의 농도는 실험군이 각 시간대 모두에서 대조군보다 유의적으로(p<0.001) 낮은 농도를 보였다. 또한 시간이 경과하면서 세 군 모두 혈중 알코올 농도는 감소하였다. 대조군의 경우 알코올 투여 1 시간경과시부터 3 시간 경과시까지의 알코올 농도는 급격하게 감소하였고, 이후 5 시간까지는 비슷한 농도가 유지되었다. 실험 1군의 경우 알코올 섭취 1 시간 후의 혈중 알코올 농도의 감소 정도는 대조군 보다 적었으며, 시간이 경과함에 따른 농도 변화가 적었다.The alcohol concentration in blood was significantly lower (p <0.001) in the experimental group than in the control group in each time period. In addition, blood alcohol levels in all three groups decreased over time. In the case of the control group, the alcohol concentration sharply decreased from 1 hour to 3 hours after alcohol administration, and remained similar until 5 hours. In the Experiment 1 group, the decrease in blood alcohol concentration after 1 hour of alcohol consumption was smaller than that of the control group, and the concentration change was less with time.
반면, 실험 2군, 3군의 경우에서는 대조군과 실험 1군보다 1 시간 후의 핼액중 알코올 농도가 급격히 감소하였으며 시간이 갈수록 더욱더 혈액중 알코올 농도가 낮아졌다. On the other hand, in the case of experimental group 2 and 3, the alcohol concentration in the solution solution drastically decreased one hour after the control group and the experimental group 1, and the blood alcohol concentration was lowered with time.
그러므로 실험 2군과 실험 3군에서는 혈액중 알코올을 빨리 분해시켜 숙취해소에 효과가 있다고 추정할 수 있다.Therefore, in Experiment 2 and Experiment 3, it can be estimated that alcohol is effective in resolving hangovers.
실험예Experimental Example 4 4
콜레스테롤 저하작용에 관한 동물실험예. Animal Experimental Example on Cholesterol-lowering Action .
체내 콜레스테롤이 축적될 경우 고콜레스테롤 혈증이 나타나며, 장기간에 걸쳐 콜레스테롤이 조절되지 않을 경우 동맥경화증으로 진행한다. 콜레스테롤 대사에서 그 합성 정도가 조절되지 않거나 혈중 콜레스테롤 농도가 지나치게 높으면 혈관벽에 콜레스테롤이 침착되어 "아테롬성 동맥경화반(atherosclerotic plaque)"이 생긴다. 1996년 제정된 한국인의 고지혈증 치료지침에 따르면 총 콜레스테롤의 수치가 200 ㎎/㎗ 이하이면 정상군으로 분류하여 2년내에 재검을 하도록 권장하고, 200-239 ㎎/㎗ 일 경우 행동요법과 식이요법을 하도록 하고 있으며, 240 ㎎/㎗ 이상일 경우 고 위험군으로 분류하여 식이요법 외에도 약물치료를 병행하도록 하고 있다.Hypercholesterolemia develops when cholesterol accumulates in the body and progresses to atherosclerosis if cholesterol is not controlled over a long period of time. If the degree of synthesis in cholesterol metabolism is unregulated or if blood cholesterol levels are too high, cholesterol is deposited on the walls of blood vessels, resulting in "atherosclerotic plaques." According to the Korean Guidelines for Treatment of Hyperlipidemia established in 1996, if the total cholesterol level is less than 200 ㎎ / ㎗, it is recommended to classify it as a normal group and reexamine within 2 years, and if it is 200-239 ㎎ / ㎗, the behavioral therapy and diet In case of more than 240 ㎎ / ㎗ is classified as a high risk group to be combined with medication in addition to diet.
총 콜레스테롤 중 LDL은 간에서 다른 조직으로 콜레스테롤을 운반하는 역할을 하므로 LDL의 콜레스테롤 함량이 높으면 관상동맥의 벽에 콜레스테롤이 쌓일 위험이 높고 따라서 LDL-콜레스테롤이 130 ㎎/㎗ 이상이면 경계선이고, 160 ㎎/㎗ 이상이면 치료가 필요하며 또한 HDL은 말초조직의 콜레스테롤을 간으로 운반하고 간에서 콜레스테롤로부터 담즙산을 합성하여 장으로 배설하므로 HDL-콜레스테롤은 동맥경화에 대한 방어효과를 가지며 HDL 콜레스테롤이 낮으면 콜레스테롤 역수송 효율이 낮아져 동맥경화의 원인이 되기 때문이다.LDL in the total cholesterol is responsible for transporting cholesterol from the liver to other tissues, so the high cholesterol content of LDL increases the risk of cholesterol accumulation in the walls of the coronary arteries, so if LDL-cholesterol is more than 130 mg / dL, it is borderline. HDL-cholesterol has a protective effect against atherosclerosis because HDL carries cholesterol from peripheral tissues to the liver and synthesizes bile acids from cholesterol in the liver to excrete into the intestine. This is because the back transportation efficiency is lowered, which causes atherosclerosis.
그러므로 장기간에 걸친 고농도의 총 콜레스테롤, 고농도의 LDL 콜레스테롤 및 저농도의 HDL 콜레스테롤은 동맥경화증을 유도하게 되며 이를 예방하기 위해서 는 약물, 식습관 교정 및 건강기능식품 등의 보충에 의한 콜레스테롤 조절이 이루어져야 한다.Therefore, long-term high concentrations of total cholesterol, high concentrations of LDL cholesterol and low concentrations of HDL cholesterol induce atherosclerosis. To prevent this, cholesterol control by supplementation with drugs, dietary supplements, and dietary supplements should be performed.
이러한 바탕에서 본 발명 건강기능성 식품을 가지고 아래의 콜레스테롤 저하작용 시험을 통하여 콜레스테롤 저하작용의 효과를 가지고 있음을 확인하였다.On the basis of the health functional food of the present invention it was confirmed that the cholesterol lowering effect through the cholesterol lowering test.
1) 시험방법 1) Test method
5-8 주령된 수컷 흰쥐를 1군 5 마리를 기준으로 정상대조군, 콜레스테롤군, 시험군 1, 시험군 2, 시험군 3 등 5 개군으로 하여 1 주간은 기본실험식이(AIN-76조성을 기본으로 Modified 된 식이)와 음용수를 자유 섭취케 하고 정상 대조군에게는 계속 기본 실험식이를 콜레스테롤군에게는 콜레스테롤농도 1.0 %를 추가하고, 그리고 시험군 1군에는 콜레스테롤군에 제제 1을 5 %, 시험군 2군에는 콜레스테롤군에 제제 2(제제예 5, 캡슐제 처방)를 5 %, 시험군 3군에는 콜레스테롤군에 제제 3(제제예 7, 액제 처방)을 5 % 추가로 넣어 4주간 사육한 다음 실험전 24 시간을 공복으로 유지한 다음 혈액을 채취하여 혈중 총콜레스테롤 및 HDL 콜레스테롤을 측정하였다. The male rats, 5-8 weeks old, were divided into five groups, including normal control group, cholesterol group, test group 1, test group 2, and test group 3, based on 5 rats in 1 week. Freely intake of modified diet) and drinking water, add basic experimental diet to the normal control group, add cholesterol concentration to 1.0% for the cholesterol group, and add 1% to the cholesterol group in the test group 1 and 5% to the test group 2 Add 5% Formulation 2 (Formulation 5, capsule formulation) to the Cholesterol group, and add 3% Formulation 3 (Formula 7, liquid formulation) to the Cholesterol group for 4 weeks. The time was kept on an empty stomach, and then blood was collected to measure total cholesterol and HDL cholesterol in the blood.
표 7. (제제설계) Table 7 . (Product Design)
표 8. (식이실험용 제제(FORMULATION OF EXPERIMENTAL DIETS)) Table 8 . (FORMULATION OF EXPERIMENTAL DIETS)
표 9. (결과 및 효과 평가) Table 9 . (Evaluation of results and effectiveness)
본 실험 결과에 의하면 시험 1군과 시험 2군, 시험 3군에서 콜레스테롤군에 비해 콜레스테롤 수치의 저하를 확인할 수 있으며 또한 고밀도 콜레스테롤(HDL) 수치도 정상에 가깝게 감소됨을 알 수가 있다. According to the results of the experiment, the test group 1, test group 2, and test group 3 can confirm the lowering of cholesterol level compared to the cholesterol group, and also the high density cholesterol (HDL) level can be seen to be close to normal.
그러므로 본 발명품도 기존 매생이 하나만을 섭취할 때와 제제 2, 제제 3 즉, 매생이, 스피루나, 해조칼슘이 함유된 제제가 콜레스테롤 저하에 더욱더 효과가 있음을 알 수 있다.Therefore, the present invention also can be seen that when the conventional intake of only one and the formulation 2, formulation 3, that is, the medicinal, spiruna, the formulation containing algae calcium is more effective in lowering cholesterol.
본 발명을 통하여 남녀노소 누구나 할 것 없이 사계절 언제, 어느 곳이든지 안전하고 휴대가 간편하고 복용이 쉬운 장기간 안정성이 확보된 매생이 함유 기능 성 건강식품을 제공할 수 있다는 특장점이 있으며, 여기에 함유되어 있는 비타민류, 단백질류, 엽록소, 아미노산 등의 영양성분들을 정제, 캡슐, 음료 등을 통하여 쉽게 섭취할 수 있음과 동시에 필요 영양성분을 공급받을 수 있으며, 숙취해소 및 콜레스테롤 저하를 시킬 수 있다는 특장점이 있다.Through the present invention, there is a feature that can provide a functional health food containing medicinal for all ages, anywhere, anytime, anywhere, anytime, anywhere, safe, easy to carry, easy to take and secured long-term stability. Nutritional ingredients such as vitamins, proteins, chlorophyll, and amino acids can be easily consumed through tablets, capsules, and beverages, and they can be supplied with the necessary nutritional ingredients, which can relieve hangovers and lower cholesterol. .
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020070033187A KR20080090101A (en) | 2007-04-04 | 2007-04-04 | Health functional foods using seaweed foods and their manufacturing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020070033187A KR20080090101A (en) | 2007-04-04 | 2007-04-04 | Health functional foods using seaweed foods and their manufacturing method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20080090101A true KR20080090101A (en) | 2008-10-08 |
Family
ID=40151487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020070033187A Abandoned KR20080090101A (en) | 2007-04-04 | 2007-04-04 | Health functional foods using seaweed foods and their manufacturing method |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20080090101A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013165131A1 (en) * | 2012-05-03 | 2013-11-07 | Cj Cheiljedang Corporation | Natural lubricant for direct compression and method for preparing natural tablet using the same |
| WO2015093663A1 (en) * | 2013-12-19 | 2015-06-25 | 에이치씨바이오텍 주식회사 | Capsosiphon fulvescens beverage and preparation method therefor |
| KR20220087825A (en) * | 2020-12-18 | 2022-06-27 | 이미숙 | Functional salt containing oyster extracts and capsosiphon fulvescens |
-
2007
- 2007-04-04 KR KR1020070033187A patent/KR20080090101A/en not_active Abandoned
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013165131A1 (en) * | 2012-05-03 | 2013-11-07 | Cj Cheiljedang Corporation | Natural lubricant for direct compression and method for preparing natural tablet using the same |
| US9827201B2 (en) | 2012-05-03 | 2017-11-28 | Cj Cheiljedang Corporation | Natural lubricant for direct compression and method for preparing natural tablet using the same |
| US10085945B2 (en) | 2012-05-03 | 2018-10-02 | Cj Cheiljedang Corporation | Natural lubricant for direct compression and method for preparing natural tablet using the same |
| WO2015093663A1 (en) * | 2013-12-19 | 2015-06-25 | 에이치씨바이오텍 주식회사 | Capsosiphon fulvescens beverage and preparation method therefor |
| KR20220087825A (en) * | 2020-12-18 | 2022-06-27 | 이미숙 | Functional salt containing oyster extracts and capsosiphon fulvescens |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101661793B1 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
| KR101738912B1 (en) | Composition For Anti-obesity And Diet | |
| CN107319525A (en) | One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof | |
| JP7393026B2 (en) | Oral composition | |
| CN107440120A (en) | A kind of children's monophagia and anorexia tailored version clinical nutrition formula particular about food and preparation method thereof | |
| KR101896024B1 (en) | Functional food compositions comprising extracts of Garcinia Cambogia as active ingredients and method for preparing the same | |
| CN103844249A (en) | Nutritional food, and preparation method thereof | |
| KR101565964B1 (en) | Composition Comprising Water Extracts from Pleurotus eryngii var. ferulea (Pf.). for Treating or Preventing hyperlipidemia | |
| CN104415188A (en) | L-carnitine tea polyphenol capsule and preparation method thereof | |
| KR102696677B1 (en) | A composition for improving, preventing and treating of obesity metabolic disease comprising Rosa multiflora root extract | |
| KR20080090101A (en) | Health functional foods using seaweed foods and their manufacturing method | |
| KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
| KR102470155B1 (en) | Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale | |
| JP2025094262A (en) | Oral Compositions | |
| CN110584120A (en) | Bone health composition | |
| KR20210041387A (en) | A natural tea removing the effect of hangover contained the extract material in arrowroot blossoms and Plantago ovata | |
| JP7090864B2 (en) | Composition | |
| JP2006104182A (en) | Composition for reducing body fat | |
| JP7401082B2 (en) | Oral composition | |
| JP2019180412A (en) | Oral composition | |
| JP5048258B2 (en) | Rebound inhibitor | |
| JP2019176828A (en) | Oral composition | |
| KR20150048698A (en) | Composition Comprising Water Extracts from Pleurotus eryngii var. ferulea (Pf.). for Treating or Preventing hyperlipidemia | |
| RU2616399C1 (en) | Method for producing biologically active product for adaptive feeding and biologically active product for adaptive feeding | |
| KR101490800B1 (en) | Composition comprising water extracts from laetiporus sulphureus var. miniatus (jungh.) imaz. for treating or preventing hyperlipidemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20070404 |
|
| PA0201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20080225 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20080526 |
|
| PG1501 | Laying open of application | ||
| NORF | Unpaid initial registration fee | ||
| PC1904 | Unpaid initial registration fee |